Vasomune Therapeutics is a biotechnology company developing compounds targeting diseases associated with vascular dysfunction and destabilization. The company’s lead compound is Vasculotide, a Tie2 receptor agonist that is being developed to treat acute lung injury (ALI) and acute kidney injury (AKI).
Why use Vasculotide?
Vasculotide aims to treat both lung and kidney injury by exploiting a conserved and critical pathophysiology, that of vascular leak. This common issue appears in many indications and has no clear therapeutic to treat it. Vasculotide fills this unmet clinical need and has been proven effective by our academic collaborations worldwide in a number of diverse models with publications in over a dozen top peer-reviewed journals and reviews.
What is Acute Lung Injury (ALI)?
Acute Lung Injury or the more severe clinical diagnosis, Acute Respiratory Distress Syndrome (ALI/ARDS) are life-threatening conditions that can develop after trauma, shock, sepsis, burns and bacterial/viral pneumonia. At its core, the critical nature of ALI/ARDS revolves around an inflammatory response within the lung. As inflammation progresses, the lungs become vulnerable to edema (fluid buildup within the lungs), which if left unmanaged can result in death. In the US and EU combined the annual incidence of ALI/ARDS is 370,000 patients. Currently there is no effective targeted therapeutic.
What is Acute Kidney Injury (AKI)?
Acute Kidney Injury (AKI) is characterized by a rapid decrease in kidney function. Major causes include ischemia reperfusion injury, infection, trauma or contrast induced nephropathy. In the United States, AKI cases exceed 550,000 per year. In critically ill patients, AKI’s prevalence may be as high as 25 to 30 per cent. Third party preclinical studies demonstrate that Vasculotide reduces AKI by minimizing inflammation, limiting vascular leak and restoring proper blood flow resulting in improved kidney function and reducing unnecessary complications to patients.
News & Events
Dec 25, 2017
In 2018 Vasomune Therapeutics will be at the 36TH ANNUAL JPM HEALTHCARE CONFERENCE, San Francisco, California